Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cardiol Therapeutics Inc. CRDL

Healthcare  —  Drug Manufacturers Specialty & Generic
1.71 (0.02) (1.16%) as of 25 Sep
Market cap
$202.1M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cardiol Therapeutics Inc. (CRDL) Business Profile

Updated before January 2025

Company Overview

Cardiol Therapeutics Inc. (CRDL) is a clinical-stage biotechnology company focused on the research, development, and commercialization of innovative anti-inflammatory therapies for the treatment of cardiovascular diseases. Founded in 2017 and headquartered in Oakville, Ontario, Canada, the company has positioned itself as a leader in the development of cannabidiol-based therapies targeting heart conditions. Cardiol Therapeutics is led by a team of seasoned professionals, including its President and CEO, David Elsley, who brings over 25 years of experience in the life sciences industry. The company’s leadership team also includes Dr. Eldon Smith, Chairman of the Board, a renowned cardiologist and former Dean of Medicine at the University of Calgary, and Dr. Andrew Hamer, Chief Medical Officer, who has extensive experience in clinical development and cardiovascular medicine.

Core Business Segments

Cardiol Therapeutics operates primarily in the biotechnology and pharmaceutical sectors, with a focus on developing therapies for cardiovascular diseases. The company’s core business segments include:

1. Cannabidiol-Based Therapeutics

Cardiol Therapeutics is leveraging the anti-inflammatory properties of pharmaceutical-grade cannabidiol (CBD) to develop treatments for heart diseases. Key products and initiatives include:

  • CardiolRx™: A proprietary, ultra-pure, high-concentration cannabidiol oral formulation designed for use in clinical trials targeting inflammatory heart conditions such as acute myocarditis and recurrent pericarditis.
  • Acute Myocarditis Program: CardiolRx™ is being evaluated in clinical trials as a potential treatment for acute myocarditis, a condition characterized by inflammation of the heart muscle.
  • Recurrent Pericarditis Program: The company is also exploring the use of CardiolRx™ for recurrent pericarditis, a condition involving repeated inflammation of the pericardium, the sac surrounding the heart.

2. Heart Failure Therapeutics

Cardiol Therapeutics is conducting research and development to address heart failure, a leading cause of hospitalization and mortality worldwide. The company’s focus includes:

  • LVEF Heart Failure Program: Investigating the potential of cannabidiol-based therapies to treat heart failure with preserved or reduced left ventricular ejection fraction (LVEF).

3. Research and Development (R&D)

The company invests heavily in R&D to advance its pipeline of innovative therapies. This includes preclinical studies, clinical trials, and collaborations with leading academic institutions and research organizations.

Business Model

Cardiol Therapeutics operates a vertically integrated business model that combines research, development, and commercialization. The company’s approach includes:

  • Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of its therapies.
  • Regulatory Approvals: Working closely with regulatory agencies such as the FDA to obtain approvals for its products.
  • Partnerships and Collaborations: Collaborating with academic institutions, research organizations, and pharmaceutical companies to accelerate drug development.
  • Revenue Generation: Cardiol Therapeutics aims to generate revenue through the commercialization of its therapies, licensing agreements, and strategic partnerships.

Strategic Direction

Cardiol Therapeutics is committed to advancing the treatment of cardiovascular diseases through innovation and collaboration. Key strategic priorities include:

  • Pipeline Expansion: Developing new therapies for additional cardiovascular conditions and exploring the potential of cannabidiol in other therapeutic areas.
  • Global Market Penetration: Expanding its presence in international markets through strategic partnerships and regulatory approvals.
  • Sustainability Goals: Ensuring sustainable business practices by prioritizing ethical sourcing, environmental responsibility, and patient-centric approaches.
  • Innovation: Investing in cutting-edge research and technology to maintain a competitive edge in the biotechnology sector.

Competitive Landscape

Cardiol Therapeutics operates in a highly competitive biotechnology and pharmaceutical industry. Key competitors include:

  • GW Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals): A leader in cannabinoid-based therapies, known for its product Epidiolex.
  • Corbus Pharmaceuticals: Focused on developing therapies for inflammatory and fibrotic diseases.
  • Arena Pharmaceuticals (acquired by Pfizer): Specializes in developing innovative therapies for cardiovascular and other diseases.
  • Amarin Corporation: Known for its cardiovascular drug Vascepa.

Cardiol Therapeutics differentiates itself through its focus on ultra-pure cannabidiol formulations and its commitment to addressing unmet medical needs in cardiovascular health.

Risk Factors

Cardiol Therapeutics faces several risks that could impact its operations and financial performance, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its therapies.
  • Market Dependence: Reliance on the success of its lead product, CardiolRx™, for revenue generation.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials and manufacturing pharmaceutical-grade cannabidiol.
  • Competition: Intense competition from established pharmaceutical companies and emerging biotech firms.
  • Clinical Trial Risks: Uncertainty surrounding the outcomes of clinical trials and potential adverse events.

Recent Developments

Cardiol Therapeutics has made significant progress in recent years, including:

  • Clinical Trials: Advancing its Phase II/III clinical trials for CardiolRx™ in acute myocarditis and recurrent pericarditis.
  • Regulatory Milestones: Receiving FDA clearance for its Investigational New Drug (IND) applications.
  • Collaborations: Partnering with leading academic institutions to conduct preclinical and clinical research.
  • COVID-19 Impact: Navigating challenges posed by the COVID-19 pandemic, including disruptions to clinical trials and supply chains.

Investment Considerations

Investors considering Cardiol Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: A robust pipeline of cannabidiol-based therapies targeting unmet medical needs.
  • Experienced Leadership: A seasoned management team with expertise in biotechnology and cardiovascular medicine.
  • Market Potential: Significant growth opportunities in the global cardiovascular therapeutics market.

Risks

  • Clinical and Regulatory Uncertainty: Dependence on successful clinical trial outcomes and regulatory approvals.
  • Financial Risks: Limited revenue generation and reliance on external funding.
  • Competitive Pressures: Intense competition from established players and emerging biotech firms.

Conclusion

Cardiol Therapeutics Inc. is a pioneering biotechnology company dedicated to transforming the treatment of cardiovascular diseases through innovative cannabidiol-based therapies. With a strong pipeline, experienced leadership, and a commitment to addressing unmet medical needs, the company is well-positioned for growth. However, investors should carefully consider the risks associated with clinical development and regulatory approvals. As Cardiol Therapeutics continues to advance its strategic priorities, it has the potential to make a significant impact on the global healthcare landscape.